Avatao Biotech
Rosetta Genomics Terminates Deal with Avatao
NEW YORK (GenomeWeb News) – Rosetta Genomics has terminated a licensing deal with Chinese diagnostic firm Avatao Biotech, the Israeli molecular diagnostic firm disclosed in a document filed with the US Securities and Exchange Commission on Monday.
Claiming Breach of Agreement, Rosetta Genomics Ending Licensing Deal with Avatao
NEW YORK (GenomeWeb News) – Rosetta Genomics said today it is terminating a licensing deal with Avatao Biotech, accusing the Chinese diagnostic firm of material breach of an agreement.
Rosetta Genomics this week announced that it has signed a definitive agreement to sell $1.9 million in stock and warrants in a private placement.